Univec, Inc. (OTCMKTS: UNVC) has been on the move northbound over the past few days since a brief dip below the $0.02-mark last week. UNVC has a very large and very loyal shareholder base that continues to accumulate at current levels. The Company continues to make great progress since getting their filings in order and going “pink current” at the end of last year. A major feat for the Company as they had fallen way behind but are now compliant and in good shape on that front with the real possibility of becoming an SEC filer and going to OTCQB. UNVC does have a history of big moves rocketing up to $0.165 in February of last year. Investors are looking for a big week ahead as the Company continues on its growth and expansion plans
UNVC has been busy in 2022, the corporate website has been advancing significant over the past few months. The Company’s OTCMarkets profile has been updated numerous times with the shell risk removed, another big step in the right direction. The Company plans to become a major player in “Wraparound Services” in the booming mental health and substance abuse environment. To that end Univec has been beefing up its BOD and management team recently adding T.I.M.E. Organization executive Lamont Ellis as new President and Lauren Herron as Vice President. They join CEO Dr. David Dalton, the first black pharmaceutical executive in the chain drug industry and a BOD that includes John C. Peoples, Past Vice President of Merck and Kenneth Grant past Vice President of Johns Hopkins Health System.
Univec, Inc. (OTCMKTS: UNVC) is an organization targeted for change in the healthcare delivery system specializing in mental health and substance misuse. The Company plans to become a major player in “Wraparound Services” in the booming mental health and substance abuse environment
UNVC is a Delaware corporation, incorporated on October 7, 1996, and the successor by merger to Univec, Inc., a New York corporation, incorporated on August 18, 1992. On March 1, 2014 the Company changed name to Univec Conglomerate, Inc. On June 19, 2021 the Company changed its name from Univec Conglomerate, Inc., to Univec, Inc., filed with the State of Delaware.
The Company is led by Dr David Dalton; a visionary who was named as one of the “Top 100 Healthcare Leaders” for 2019 by the International Forum on Advancements in Healthcare. With 45 years’ experience in the pharmaceutical world, Dr. Dalton served over 18 years as Vice President of Rite Aid, and then founded and served as Chairman, President, CEO of several successful pharmaceutical and pharmaceutical related companies including Mednet, ManagedcareRx, and Sivault Systems. Dr. Dalton is an inductee of three Halls of Fame, has received recognition from several presidents of the United States, and is a recipient of the Senatorial-Medal of Freedom. Dr. Dalton received a Doctor of Pharmacy from West Virginia University School of Pharmacy. In addition to his extensive background in pharmaceutical field, he is a visiting professor and lectures at several schools of pharmacy throughout the United States, and former President of West Virginia University School of Pharmacy Presidential Committee. Dr Dalton has built an impressive BOD for UNVC including John C. Peoples, Past Vice President of Merck as well as Kenneth Grant past Vice President of Johns Hopkins Health System.
In August of last year, the Company announced the signing of a binding term sheet for the acquisition of accredited outpatient mental health centers in Maryland. These centers are community-based centers which provide outpatient mental health counseling treatment for substance abuse and other ancillary services. The acquisition will add in excess of $17million in topline revenue to Univec and is expected to close on or around September 30, 2021 subject to final due diligence and valuation.
— IDIG INVESTMENTS (@IDIG_INVESTMENT) May 15, 2022
To Find out the inside Scoop on UNVC Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
This was when Univec’s business plan for “Wraparound Services” in the mental health and substance abuse environment was first revealed. These are enormous markets worth hundreds of billions where there is a lot of opportunity for a smart Company with good management. The US is in the midst of a mental health and substance abuse pandemic with over 100,000 people dying or overdose every year and new ideas are needed to address the problem. Univec intends to be at the forefront of delivering targeted care in the mental health arena by treating multiple aspects of the issues.
In October Univec formed a partnership with bioRemedies MD, LLC, to offer safe adjunct therapies for pain, anxiety, and sleep disorders. bioRemedies MD’s proprietary cannabinoid-based products will be used by UNIVEC, Inc. in clinical behavioral health settings for out-patient treatment. bioRemedies MD specializes in cannabinoid-complementary and -integrative products. Their products have been in research and development at the company’s University of Maryland BioPark lab since industrial hemp research was legitimized 2016.
bioRemedies MD’s scientifically formulated cannabinoid products are unlike anything on the market today. Through the use of FDA and pharmaceutical processes, technology, and standards, bioRemedies MD has been able to ensure high-quality, reproducible, and targeted formulations. Their proprietary nanotechnology delivers cannabinoids efficiently and effectively, a requirement for academic research and healthcare target markets, and allows their commercial products to compete on quality and cost. UNIVEC, Inc. will make private label and bioRemedies MD products available through several distribution channels throughout the U.S. market, including recently acquired community-based outpatient mental health centers. The partnership with bioRemedies MD is consistent with being in the forefront of delivering targeted care using custom-blend multi cannabinoid adjunct therapies.”
UNIVEC, Inc. is working to change the way healthcare is delivered in the United States. The company works with several community-based outpatient mental health centers to treat behavioral health. bioRemedies MD complements UNIVEC, Inc. principles—treating the patient as a whole and applying “total wraparound” support for patients, families, and caregivers.
UNVC has been busy beefing up its management team; they added Lamont Ellis as their new President. Ellis has more than 22 years growing and expanding T.I.M.E. Organization, Inc., a licensed Outpatient Mental Health Center (OMHC) providing community based mental health and behavioral health services including counseling, PRP, substance abuse, services and other wraparound services. The tireless efforts and visionary leadership of Ellis has grown T.I.M.E. to a$20,000,000 revenue organization.
UNVC also appointed Lauren Herron as Vice President. Ms. Herron earned a Bachelor’s degree in social work and Sociology and Masters in Social work graduating Cum Laude from the University of Maryland. She said “I look forward to joining Univec, Inc. as Vice President addressing the mental health and medical needs of our communities by promoting an affordable, holistic approach as the model of treatment.”
Daughter (Chaitra Dalton Bryant) and Son-in-law (John Hope Bryant) ringing the Nasdaq bell this morning. pic.twitter.com/uTjtqdu0y7
— Dr. David Dalton (@DrDavidDalton1) April 5, 2022
For More on UNVC Subscribe Right Now!
Currently trading at a $56 million market valuation UNVC is on the rise since a major reversal that started last week after a brief dip below the $0.02 mark. The Company is gearing up for something big, beefing up its BOD and management team as it embarks on its plan to become a major player in “Wraparound Services” in the booming mental health and substance abuse environment. Investors are looking for a big week ahead as the Company continues on its growth and expansion plans. Like any penny stocks UNVC has its risks, although the risk reward ratio was raised significantly when the Company became “pink current” got the shell risk removed and filed their annual report 2 weeks early with OTCmarkets. UNVC speculators are looking for a break back to previous highs and beyond as the Company continues to executive in 2022. Microcapdaily first reported on UNVC on October 28, 2018 when the stock was around $0.005 long before it ran to $0.165 up 3,000% from our first article. We will be updating on UNVC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with UNVC.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in UNVC either long or short and we have not been compensated for this article.